Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:469679.
doi: 10.1155/2011/469679. Epub 2011 Dec 13.

Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease)

Carlos Spuch  1 , Carmen Navarro
Affiliations

Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease)

Carlos Spuch et al. J Drug Deliv. 2011.

Abstract

Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease represent a huge unmet medical need. The prevalence of both diseases is increasing, but the efficacy of treatment is still very limited due to various factors including the blood brain barrier (BBB). Drug delivery to the brain remains the major challenge for the treatment of all neurodegenerative diseases because of the numerous protective barriers surrounding the central nervous system. New therapeutic drugs that cross the BBB are critically needed for treatment of many brain diseases. One of the significant factors on neurotherapeutics is the constraint of the blood brain barrier and the drug release kinetics that cause peripheral serious side effects. Contrary to common belief, neurodegenerative and neurological diseases may be multisystemic in nature, and this presents numerous difficulties for their potential treatment. Overall, the aim of this paper is to summarize the last findings and news related to liposome technology in the treatment of neurodegenerative diseases and demonstrate the potential of this technology for the development of novel therapeutics and the possible applications of liposomes in the two most widespread neurodegenerative diseases, Alzheimer's disease and Parkinson's disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of the basic structure of unilamellar liposomes (a) and multilamellar liposomes (b). The aqueous core of the liposome, loaded with the drug, is surrounded by a phospholipid bilayer.
Figure 2
Figure 2
The antibodies of the immunoliposomes recognise the specific receptor of the BBB releasing the drug of the immunoliposomes only close to the targeting cells.
Figure 3
Figure 3
Schematic representation of different types of liposomes. (a) Conventional liposome, (b) conventional liposome tagged directly with antibodies, (c) stealth liposome coated with a polymeric conjugated, (d) liposome coated with a polymeric conjugated tagged with antibodies, (e) liposome coated with a specific ligand.
Figure 4
Figure 4
A Schematic representation of a DNA-Liposome complex.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. OECD. OECD, Health at a Glance: Europe 2010. OECD Publishing; 2010. Dementia prevalence; pp. 54–55.
    1. Forlenza OV, Diniz BS, Gattaz WF. Diagnosis and biomarkers of predementia in Alzheimer’s disease. BMC Medicine. 2010;8:p. 89. - PMC - PubMed
    1. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. Journal of Clinical Investigation. 2005;115(6):1449–1457. - PMC - PubMed
    1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112–2117. - PMC - PubMed
    1. American Health Assistance Foundation. Alzheimer disease research: about Alzheimer. http://www.ahaf.org/alzheimers/

LinkOut - more resources